Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087854 · ClinicalTrials.gov registry record · Phase 1
Study of Individualized Amonafide to Treat Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Xanthus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT00087854: Completed Phase 1 study of Prostate Cancer, sponsored by Xanthus Pharmaceuticals.
NCT00087854 is a Phase 1 study of Prostate Cancer that has completed, run by Xanthus Pharmaceuticals. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087854, a Phase 1 study of Prostate Cancer, has completed, sponsored by Xanthus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
Conditions Studied
Interventions
- DRUG Amonafide L-malate (drug)
Study Locations (8)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Maryland
- Cancer Center at John Hopkins - Baltimore
Missouri
- Barnard Cancer Center - St Louis
New Jersey
- Cancer Institute of New Jersey - New Brunswick
New York
- Herbert Irving Cancer Center - New York
Ohio
- The Cleveland Clinic - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
What the finished NCT00087854 record still lists
NCT00087854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Amonafide L-malate (drug) is the first listed.
NCT00087854 lists 8 locations in 8 states (California, Maryland, Missouri).
Frequently Asked Questions
What is clinical trial NCT00087854 about?
NCT00087854 is a clinical study titled "Study of Individualized Amonafide to Treat Prostate Cancer". The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
What is the current status of trial NCT00087854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-03. Estimated completion is 2005-12.
What conditions does trial NCT00087854 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00087854?
The interventions under investigation include: Amonafide L-malate (drug) (DRUG).
Who is sponsoring clinical trial NCT00087854?
This trial is sponsored by Xanthus Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087854 being conducted?
This trial has 8 study locations across California, Maryland, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00087854's enrollment target sits among peer trials
40 526th of 735 higher than 201 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia